Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 13/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 12/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.51 |
| ▸ | ATM | Q13315 | 13/20 | 0.46 |
| ▸ | ATR | Q13535 | 9/20 | 0.46 |
| ▸ | PIK3C2A | O00443 | 2/20 | 0.43 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.43 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.43 |
| ▸ | PRKDC | P78527 | 2/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.43 |
| ▸ | LTK | P29376 | 1/20 | 0.43 |
| ▸ | CDK7 | P50613 | 1/20 | 0.43 |
| ▸ | NEK2 | P51955 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2068484 | 0.90 | MTOR (0.51) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL2068022 | 0.89 | MTOR (0.51) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL2067739 | 0.89 | MTOR (0.48) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL2068505 | 0.88 | MTOR (0.52) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL2068151 | 0.87 | MTOR (0.47) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL2069211 | 0.86 | MTOR (0.51) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3516902 | 0.86 | MTOR (0.50) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL2068407 | 0.85 | ATM (0.47) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL2067761 | 0.84 | ATM (0.52) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL2068075 | 0.84 | ATM (0.49) | MTORPIK3CAPIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438063-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2012-04-11 | — | — | EP | claimed |
| WO-2010139747-A1 | 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | claimed |
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | NOVARTIS AG (CH) | 2010-12-09 | — | — | US | claimed |
| EP-2438063-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2012-04-11 | — | — | EP | disclosed |
| WO-2010139747-A1 | 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010139747-A1 | 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | disclosed |
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | NOVARTIS AG (CH) | 2010-12-09 | — | — | US | disclosed |
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | NOVARTIS AG (CH) | 2010-12-09 | — | — | US | disclosed |
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | NOVARTIS AG (CH) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | PRKCA, ABL1, MYLK2 | MTOR 326/4885PIK3CA 83/4885PIK3CD 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.